Novartis
NEWS
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
Novartis announced that it has completed its acquisition of Xiidra® 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
According to the poll results, 78% of respondents agree that the high costs of a gene therapy treatment are worth it, due to the fact that these options are seen as potential cures for disease.
Conatus indicated that it is considering a sale of the company as part of an exploration of strategic alternatives. It is already implementing a restructuring plan that will cut 40% of staff and suspend development of its inflammasome compound CTS-2090.
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
JOBS
IN THE PRESS